U.S. markets open in 2 hours 20 minutes
  • S&P Futures

    3,946.75
    +10.00 (+0.25%)
     
  • Dow Futures

    33,686.00
    +61.00 (+0.18%)
     
  • Nasdaq Futures

    11,537.25
    +27.75 (+0.24%)
     
  • Russell 2000 Futures

    1,813.10
    +5.10 (+0.28%)
     
  • Crude Oil

    73.28
    +1.27 (+1.76%)
     
  • Gold

    1,795.60
    -2.40 (-0.13%)
     
  • Silver

    22.92
    -0.01 (-0.03%)
     
  • EUR/USD

    1.0514
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    3.4080
    0.0000 (0.00%)
     
  • Vix

    22.79
    +0.62 (+2.80%)
     
  • GBP/USD

    1.2170
    -0.0035 (-0.29%)
     
  • USD/JPY

    136.8130
    +0.2890 (+0.21%)
     
  • BTC-USD

    16,865.73
    +62.85 (+0.37%)
     
  • CMC Crypto 200

    396.59
    -5.44 (-1.35%)
     
  • FTSE 100

    7,487.79
    -1.40 (-0.02%)
     
  • Nikkei 225

    27,574.43
    -111.97 (-0.40%)
     

The President of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), Raul Rodriguez, Just Bought 521% More Shares

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) shareholders (or potential shareholders) will be happy to see that the President, Raul Rodriguez, recently bought a whopping US$688k worth of stock, at a price of US$0.69. That purchase boosted their holding by 521%, which makes us wonder if the move was inspired by quietly confident deeply-felt optimism.

Check out our latest analysis for Rigel Pharmaceuticals

The Last 12 Months Of Insider Transactions At Rigel Pharmaceuticals

In fact, the recent purchase by Raul Rodriguez was the biggest purchase of Rigel Pharmaceuticals shares made by an insider individual in the last twelve months, according to our records. We do like to see buying, but this purchase was made at well below the current price of US$0.81. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price.

You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

insider-trading-volume
insider-trading-volume

Rigel Pharmaceuticals is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Does Rigel Pharmaceuticals Boast High Insider Ownership?

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. From looking at our data, insiders own US$1.1m worth of Rigel Pharmaceuticals stock, about 0.8% of the company. We consider this fairly low insider ownership.

So What Do The Rigel Pharmaceuticals Insider Transactions Indicate?

It is good to see the recent insider purchase. And the longer term insider transactions also give us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. We would certainly prefer see higher levels of insider ownership but analysis of the insider transactions suggests that Rigel Pharmaceuticals insiders are expecting a bright future. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. While conducting our analysis, we found that Rigel Pharmaceuticals has 2 warning signs and it would be unwise to ignore these.

But note: Rigel Pharmaceuticals may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.